These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9076775)

  • 41. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
    Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
    J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
    Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results.
    Paganelli G; Bartolomei M; Ferrari M; Cremonesi M; Broggi G; Maira G; Sturiale C; Grana C; Prisco G; Gatti M; Caliceti P; Chinol M
    Cancer Biother Radiopharm; 2001 Jun; 16(3):227-35. PubMed ID: 11471487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts.
    Wilder RB; Langmuir VK; Mendonca HL; Goris ML; Knox SJ
    Cancer Res; 1993 Jul; 53(13):3022-7. PubMed ID: 8319209
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates.
    Harrison A; Walker CA; Parker D; Jankowski KJ; Cox JP; Craig AS; Sansom JM; Beeley NR; Boyce RA; Chaplin L
    Int J Rad Appl Instrum B; 1991; 18(5):469-76. PubMed ID: 1917516
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
    Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
    Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 90Y.B72.3 against pancreatic cancer: dosimetric and biological analysis.
    Mehta MP; Kubsad SS; Fowler JF; Verma AK; Hsieh JT; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 1990 Sep; 19(3):627-31. PubMed ID: 2211210
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts.
    Roselli M; Milenic DE; Brechbiel MW; Mirzadeh S; Pippin CG; Gansow OA; Colcher D; Schlom J
    Cancer Biother Radiopharm; 1999 Jun; 14(3):209-20. PubMed ID: 10850305
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.
    Knox SJ; Goris ML; Tempero M; Weiden PL; Gentner L; Breitz H; Adams GP; Axworthy D; Gaffigan S; Bryan K; Fisher DR; Colcher D; Horak ID; Weiner LM
    Clin Cancer Res; 2000 Feb; 6(2):406-14. PubMed ID: 10690517
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
    Goodwin DA; Meares CF; Osen M
    J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biological evaluation of avidin-based tumor pretargeting with DOTA-Triazole-Biotin constructed via versatile Cu(I) catalyzed click chemistry.
    Uppal JK; Varshney R; Hazari PP; Chuttani K; Kaushik NK; Mishra AK
    J Drug Target; 2011 Jul; 19(6):418-26. PubMed ID: 20678008
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y-labeled monoclonal antibody CO17-1A prepared by two bifunctional chelate techniques.
    Lee YC; Washburn LC; Sun TT; Byrd BL; Crook JE; Holloway EC; Steplewski Z
    Cancer Res; 1990 Aug; 50(15):4546-51. PubMed ID: 2164441
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody.
    Kobayashi H; Wu C; Kim MK; Paik CH; Carrasquillo JA; Brechbiel MW
    Bioconjug Chem; 1999; 10(1):103-11. PubMed ID: 9893971
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin.
    Breitz HB; Weiden PL; Beaumier PL; Axworthy DB; Seiler C; Su FM; Graves S; Bryan K; Reno JM
    J Nucl Med; 2000 Jan; 41(1):131-40. PubMed ID: 10647616
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model.
    Marshall D; Pedley RB; Boden JA; Boden R; Begent RH
    Br J Cancer; 1994 Mar; 69(3):502-7. PubMed ID: 8123481
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+.
    Breeman WA; De Jong MT; De Blois E; Bernard BF; De Jong M; Krenning EP
    Nucl Med Biol; 2004 Aug; 31(6):821-4. PubMed ID: 15246375
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts.
    Buchsbaum DJ; Lawrence TS; Roberson PL; Heidorn DB; Ten Haken RK; Steplewski Z
    Int J Radiat Oncol Biol Phys; 1993 Mar; 25(4):629-38. PubMed ID: 8454481
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A radioiodinated biocytin derivative for in-vivo applications.
    Nakamoto Y; Sakahara H; Saga T; Yao Z; Zhang M; Sato N; Zhao S; Arano Y; Ono M; Saji H; Konishi J
    Nucl Med Commun; 1998 Oct; 19(10):963-9. PubMed ID: 10234676
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT).
    Urbano N; Papi S; Ginanneschi M; De Santis R; Pace S; Lindstedt R; Ferrari L; Choi S; Paganelli G; Chinol M
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):68-77. PubMed ID: 16755333
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improved tumor targeting and decreased normal tissue accumulation through extracorporeal affinity adsorption in a two-step pretargeting strategy.
    Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5572s-5576s. PubMed ID: 17875791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.